MAFLD criteria overlooks a number of patients with severe steatosis: Is it clinically relevant?

J Hepatol. 2020 Nov;73(5):1265-1267. doi: 10.1016/j.jhep.2020.06.016. Epub 2020 Aug 17.

Authors

Jiaofeng Huang¹, Rahul Kumar², Mingfang Wang¹, Yueyong Zhu¹, Su Lin³

Affiliations

¹ Liver Research Center of the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China, 350001.
² Department of Gastroenterology and Hepatology, Duke-NUS Academic Medical Centre, Changi General Hospital, Singapore.
³ Liver Research Center of the First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China, 350001. Electronic address: [email protected].

PMID: 32819754
DOI: 10.1016/j.jhep.2020.06.016

No abstract available

Keywords: Metabolic associated fatty liver disease; Metabolic risk; NHANES; Non-alcoholic fatty liver disease.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Consensus
Humans
Non-alcoholic Fatty Liver Disease* / diagnosis
Non-alcoholic Fatty Liver Disease* / epidemiology